ArticleNucleic acids research2017
Functional RNAs: combined assembly and packaging in VLPs.
Article in Nucleic acids research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 48 citations in OpenAlex.
- Virus-like particles in cancer immunotherapy: bridging human and veterinary medicine through one health.Journal of nanobiotechnology · 2026Review
- Encapsulin-Protected Immunotherapeutic Complexes: Bacteria-Derived Nanoparticles for mRNA Delivery to Eukaryotic Cells.ChemMedChem · 2026Article
- Review
- Identification and characterization of a novel plaque-invisible lytic single-stranded RNA phage.Journal of virology · 2025Article
- Proof of concept for a single-dose Group B Streptococcus vaccine based on capsular polysaccharide conjugated to Qβ virus-like particles.NPJ vaccines · 2023Article
- Bioengineered Bacteriophage-Like Nanoparticles as RNAi Therapeutics to Enhance Radiotherapy against Glioblastomas.ACS nano · 2023Article
- Engineered Protein Nanocages for Concurrent RNA and Protein Packaging In Vivo.ACS synthetic biology · 2022Article
- Virus-like Particles as Nanocarriers for Intracellular Delivery of Biomolecules and Compounds.Viruses · 2022Review
- Plant-Based Vaccines: Antigen Design, Diversity, and Strategies for High Level Production.Vaccines · 2022Review
- In Vitro Assembly of Virus-Like Particles and Their Applications.Life (Basel, Switzerland) · 2021Review
- Review
- Asymmetric bifunctional protein nanoparticles through redesign of self-assembly.Nanoscale advances · 2019Article
- Protein-based vehicles for biomimetic RNAi delivery.Journal of biological engineering · 2019Review
- Review
- RNA: packaged and protected by VLPs.RSC advances · 2018Article
- Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy.The Journal of pharmacology and experimental therapeutics · 2018Article
- Protein cage assembly across multiple length scales.Chemical Society reviews · 2018Review
- Construction of Multifunctional FeNanotheranostics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe here a one pot RNA production, packaging and delivery system based on bacteriophage Qβ. We demonstrate a method for production of a novel RNAi scaffold, packaged within Qβ virus-like particles (VLPs). The RNAi scaffold is a general utility chimera that contains a functional RNA duplex with paired silencing and carrier sequences stabilized by a miR-30 stem-loop. The Qβ hairpin on the 5΄ end confers affinity for the Qβ coat protein (CP). Silencing sequences can include mature miRNAs and siRNAs, and can target essentially any desired mRNA. The VLP-RNAi assembles upon co-expression of CP and the RNAi scaffold in E. coli. The annealing of the scaffold to form functional RNAs is intramolecular and is therefore robust and concentration independent. We demonstrate dose- and time-dependent inhibition of GFP expression in human cells with VLP-RNAi. In addition, we target the 3΄UTR of oncogenic Ras mRNA and suppress Pan-Ras expression, which attenuates cell proliferation and promotes mortality of brain tumor cells. This combination of RNAi scaffold design with Qβ VLP packaging is demonstrated to be target-specific and efficient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.